Patients with advanced esophageal cancer, melanoma and sarcoma.
Conditions
Sponsors
UZ Brussel
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Advanced cancer, locally or metastatic - Second line treatment ( prior targeted treatments not directly involving angiogenesis are permitted) - Presence of plasma and tissue sample - Disease progression on prior treatment and antitumour therapy-free period of > 4 weeks before baseline examination for current study - Sarcoma: second line, after one line of anthracycline based chemotherapy - Melanoma: second line, after one line chemotherapy containing DTIC. Prior vaccination and anti-CTLA4 immune therapy allowed - Esophageal cancer: second line after cisplatinum based chemotherapy Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Evaluate the objective respons rate as defined by the RECIST method for patients with advanced esophageal cancer, melanoma and sarcoma. ;Secondary Objective: - Evaluate progression free survival at 6 months - Evaluate overall survival - Evaluate safety and tolerability - Investigate the correlation between response and translational parameters ;Primary end point(s): Objective response rate. | — |
Countries
Belgium
Outcome results
None listed